Thomas Würdinger

Thomas Wurdinger currently serves as a member of the Board of Directors at Cellab and Omnio AB, while also being the founder of Reunion Capital, an investment fund focused on early-stage biotech start-ups. As a professor at Amsterdam UMC since February 2008, Thomas directs the neuro-oncology research group, dedicated to eradicating brain cancer. Previous roles include Head of Nucleic Acid Research at GRAIL, Inc., and Chief Scientific Officer at thromboDx. Thomas completed a PhD in Virology and Oncology at Utrecht University and holds a Master's degree in Biology from Vrije Universiteit Amsterdam.